Company registration number 03370027 (England and Wales)
S.L.A. PHARMA (UK) LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
S.L.A. PHARMA (UK) LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
S.L.A. PHARMA (UK) LTD
BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
26,849
30,130
Current assets
Debtors
4
412,662
464,630
Cash at bank and in hand
79,703
19,062
492,365
483,692
Creditors: amounts falling due within one year
6
(259,792)
(524,964)
Net current assets/(liabilities)
232,573
(41,272)
Total assets less current liabilities
259,422
(11,142)
Creditors: amounts falling due after more than one year
5
(2,121)
(13,307)
Provisions for liabilities
(4,798)
(5,724)
Net assets/(liabilities)
252,503
(30,173)
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
252,403
(30,273)
Total equity
252,503
(30,173)
S.L.A. PHARMA (UK) LTD
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2025
31 March 2025
- 2 -

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 19 November 2025 and are signed on its behalf by:
Mr J R Slagel
Director
Company registration number 03370027 (England and Wales)
S.L.A. PHARMA (UK) LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
1
Accounting policies
Company information

S.L.A. Pharma (UK) Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 3a Chestnut House, Farm Close, Shenley, Hertfordshire, United Kingdom, WD7 9AD.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Going concern

The company continues to receive financial support from it's associated company. Therefore, the director considers it appropriate to prepare these financial statements on a going concern basis. true

1.3
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

 

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% reducing balance
Computers
33% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

S.L.A. PHARMA (UK) LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 4 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.6
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.7
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
4
4
S.L.A. PHARMA (UK) LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 5 -
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 April 2024
117,304
Additions
5,688
Disposals
(1,624)
At 31 March 2025
121,368
Depreciation and impairment
At 1 April 2024
87,174
Depreciation charged in the year
8,969
Eliminated in respect of disposals
(1,624)
At 31 March 2025
94,519
Carrying amount
At 31 March 2025
26,849
At 31 March 2024
30,130
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
183,104
-
0
Corporation tax recoverable
46,970
404,735
Other debtors
182,588
59,895
412,662
464,630
5
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
2,121
13,307
S.L.A. PHARMA (UK) LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 6 -
6
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
10,380
10,560
Trade creditors
156,423
419,144
Taxation and social security
3,503
27,244
Other creditors
89,486
68,016
259,792
524,964
2025-03-312024-04-01falsefalsefalse19 November 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityMr J R SlagelMrs L J Nachoom-Slagel033700272024-04-012025-03-31033700272025-03-31033700272024-03-3103370027core:OtherPropertyPlantEquipment2025-03-3103370027core:OtherPropertyPlantEquipment2024-03-3103370027core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3103370027core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3103370027core:ShareCapital2025-03-3103370027core:ShareCapital2024-03-3103370027core:RetainedEarningsAccumulatedLosses2025-03-3103370027core:RetainedEarningsAccumulatedLosses2024-03-3103370027bus:Director12024-04-012025-03-3103370027core:FurnitureFittings2024-04-012025-03-3103370027core:ComputerEquipment2024-04-012025-03-31033700272023-04-012024-03-3103370027core:OtherPropertyPlantEquipment2024-03-3103370027core:OtherPropertyPlantEquipment2024-04-012025-03-3103370027core:CurrentFinancialInstruments2025-03-3103370027core:CurrentFinancialInstruments2024-03-3103370027core:WithinOneYear2025-03-3103370027core:WithinOneYear2024-03-3103370027core:Non-currentFinancialInstruments2025-03-3103370027core:Non-currentFinancialInstruments2024-03-3103370027bus:PrivateLimitedCompanyLtd2024-04-012025-03-3103370027bus:SmallCompaniesRegimeForAccounts2024-04-012025-03-3103370027bus:FRS1022024-04-012025-03-3103370027bus:AuditExemptWithAccountantsReport2024-04-012025-03-3103370027bus:Director22024-04-012025-03-3103370027bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP